| HOME >> MEDICINE >> TECHNOLOGY |
Company Overview 130
Products and Services 130
Company Strategy 130
BIOSYSTEMS INTERNATIONAL INC 131
Company Overview 131
Products and Services 131
Company Strategy 131
CAPRION PROTEOMICS INC 132
Company Overview 132
Products and Services 132
Company Strategy 132
CLINICAL DATA, INC 133
Company Overview 133
Products and Services 133
Company Strategy 133
CORRELOGIC SYSTEMS, INC 134
Company Overview 134
Products and Services 134
Company Strategy 134
EPIGENOMICS AG 135
Company Overview 135
Products and Services 135
Company Strategy 135
GENEDATA AG 136
Company Overview 136
Products and Services 136
Company Strategy 137
GENEGO, INC 137
Company Overview 137
Products and Services 137
Company Strategy 137
GENENEWS LTD 138
Company Overview 138
Products and Services 138
Company Strategy 139
CHAPTER SIX: NEXT-GENERATION CARDIOVASCULAR THERAPIES 140
SUMMARY 140
TABLE 58 GLOBAL CARDIOVASCULAR FORECAST BY DISEASE,
THROUGH 2015 ($ MILLIONS) 141
EMERGING DRUG CLASSES 142
P2Y12 AND FACTOR XA INHIBITORS 142
TABLE 59 CARDIOVASCULAR MARKET FORECAST BY DRUG
CLASS, THROUGH 2015 142
TABLE 59 (CONTINUED) 143
Effient (Prasugrel): a Leading P2Y12 Antagonist 143
TABLE 60 P2Y12 MARKET GROWTH AND SHARE, THROUGH 2010 ($
MILLIONS) 144
TABLE 61 PY12 MARKET FORECAST, THROUGH 2015 ($ MILLIONS) 144
TABLE 62 FACTOR XA CURRENT MARKET GROWTH AND SHARE ($
MILLIONS) 145
TABLE 63 FACTOR XA MARKET FORECAST, THROUGH 2015 ($
MILLIONS) 145
P2Y12 Inhibitors and Antagonists 145
Factor Xa Inhibitors 146
Cholesterol-Ester Transfer Protein (CETP) Inhibitor 146
TABLE 64 CETP INHIBITORS IN ACTIVE DEVELOPMENT 147
'/>"/>| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |